Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of December 2024, with a filing date of December 30, 2024. The document serves as a notice for a Special General Meeting of Shareholders scheduled for February 5, 2025, at the company's offices in Rehovot, Israel. The filing incorporates by reference the Notice of Meeting, Proxy Statement, and Proxy Card as Exhibits 99.1, 99.2, and 99.3.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance notification regarding a shareholder meeting and does not contain financial performance data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The document focuses solely on the procedural details of the upcoming shareholder vote.
Guidance, Outlook, and Corporate Actions
- Special Meeting: Scheduled for February 5, 2025, at 3:00 p.m. Israel time.
- Record Date: Shareholders of record as of the close of business on January 6, 2025, are entitled to vote.
- Proposal Details: Specifics regarding the proposal to be voted on are contained in the attached Proxy Statement (Exhibit 99.2), which is incorporated by reference but not detailed in the main body of this summary text.
- Voting Mechanism: A proxy card (Exhibit 99.3) is distributed to shareholders as the primary means to cast votes.
Key Facts for Investor Verification
- Verify the specific proposal details in the attached Proxy Statement (Exhibit 99.2) to understand the business rationale for the special meeting.
- Confirm the record date of January 6, 2025, to determine voting eligibility.
- Review the required majority for approval of the proposal as outlined in the Notice of Meeting (Exhibit 99.1).
- Note that this filing incorporates documents into existing registration statements on Form F-3 and Form S-8.